Approved Rare Disease Deal Benchmarks

Approved rare disease licensing deals carry a median total deal value of $6.3B, with upfront payments ranging from $1.8B to $3.1B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 41% to upfront and 59% to milestones.

The rare disease landscape at the approved stage is characterized by limited competitive intensity per indication but growing platform competition. Development milestones average $186M, regulatory milestones contribute $446M, and commercial milestones reach $3.1B. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths.